Kera Capital Partners Inc. Invests $351,000 in Johnson & Johnson (NYSE:JNJ)

Kera Capital Partners Inc. acquired a new position in Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,430 shares of the company's stock, valued at approximately $351,000.

A number of other institutional investors have also recently bought and sold shares of JNJ. Taylor & Morgan Wealth Management LLC lifted its holdings in Johnson & Johnson by 29.4% during the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 4,572 shares of the company's stock valued at $661,000 after purchasing an additional 1,038 shares during the last quarter. TruWealth Advisors LLC raised its position in shares of Johnson & Johnson by 2.9% during the 4th quarter. TruWealth Advisors LLC now owns 5,652 shares of the company's stock valued at $817,000 after buying an additional 161 shares in the last quarter. HB Wealth Management LLC lifted its stake in Johnson & Johnson by 1.7% during the fourth quarter. HB Wealth Management LLC now owns 207,479 shares of the company's stock worth $30,003,000 after purchasing an additional 3,460 shares during the last quarter. Financial & Tax Architects LLC lifted its position in Johnson & Johnson by 6.0% in the 4th quarter. Financial & Tax Architects LLC now owns 41,533 shares of the company's stock worth $6,006,000 after buying an additional 2,347 shares during the last quarter. Finally, Gill Capital Partners LLC boosted its stake in shares of Johnson & Johnson by 14.8% in the 4th quarter. Gill Capital Partners LLC now owns 2,168 shares of the company's stock valued at $314,000 after purchasing an additional 279 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.7 %

Shares of JNJ stock traded up $1.07 during trading hours on Tuesday, hitting $148.10. 11,094,063 shares of the company's stock traded hands, compared to its average volume of 8,798,511. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock's fifty day simple moving average is $148.35 and its two-hundred day simple moving average is $156.11. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The stock has a market cap of $356.57 billion, a price-to-earnings ratio of 21.43, a PEG ratio of 2.39 and a beta of 0.51.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.35%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's payout ratio is currently 71.78%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on JNJ. Royal Bank of Canada boosted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 16th. Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They set an "outperform" rating and a $190.00 target price for the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a report on Wednesday, October 16th. Finally, Barclays cut their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set an "equal weight" rating on the stock in a report on Tuesday. Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $173.27.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the firm's stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.